KRAS and neoplasm: Although almost 70% of patients with NSCLC present with locally advanced or metastatic disease at the time of diagnosis [16,17], KRAS and EGFR mutation status is most commonly assessed only in the primary tumor tissue based on the assumption that primary and metastases are pathologically concordant.